Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production (iConsensus)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Germany,Germany,Germany,Germany,Germany,Germany,Germany,Belgium,Belgium,Sweden,France,Netherlands,Netherlands,Netherlands,Denmark,United Kingdom,United Kingdom,Denmark
Call: Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes (H2020-JTI-IMI2-2016-10-two-stage, 2016)
Start date: 2018-05-01
End date: 2022-10-31
Duration (months): 54.0
Total project cost (EUR): 9400000.0
EU funding (EUR): 4700000.0
Participants: 22
Project status: SIGNED

iConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and control of mammalian cell cultivation process producing biopharmaceuticals. iConsensus will develop an analytical platform with on-line/at-line sensors and detection methods measuring multiple factors in the cell culture and the produced biopharmaceutical. Under advanced data management, the analytical platform will be integrated in new micro-bioreactors for HTP screening on one hand and in classical stirred tank vessel bioreactor on the other hand. Based on the analytical information, feedback control will be applied. When deemed suitable, implementation in GMP production of the sensing and control tools will be carried on.

Keywords: at line analysis,on line analysis,biopharmaceutical,drug protein,high throughput bioreactor
Small scale farmers’ sustainable adaptation strategies to climate change based on ecosystem services (ADAFARM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Society and Enterprise panel
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-10-01
End date: 2020-11-30
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

ADAFARM aims to analyze ecosystem-based climate adaptation options and nature based solutions for small farmers in sub-Saharan Africa. In line with the SDGS these strategies would be economically efficient, environmentally sustainable and socially equitable. I will use a social-ecological frame to focus on the role played by formal and informal institutions and key factors like poverty and gender for ecosystem based adaptation strategies to climate change. I will build on data, results and stakeholder networks from the ACES project. ACES was a 3 year research project, funded by the UK government (2 M. €) with the aim of analyzing the consequences from the loss of ecosystem services from deforestation to the livelihoods of poor rural communities. I will further analyze data from a survey done to more than 1600 households, with new lenses: the adaptation of small scale farmers (especially women headed households) to climate change and in particular the role of institutions. To complete the research, I will perform new qualitative data collection, through interviews and focus groups, to complete our understanding of the climate change adaptation options for small scale farmers. I am currently working at ICATALIST, an innovative SME specialized in knowledge brokerage, applied research and capacity building related to socio-ecological systems and adaptation to climate change. Working at ICATALIST will allow me to eventually transfer and scale the project to other areas with real and plausible interventions to design and help implement adaptation strategies to improve the resilience of small scale farmers. ICATALIST aims to play a leading role in the climate change adaptation policy space, with viable financing solutions for development (and thus the SDGs). This project will provide in-depth knowledge and approaches to help develop climate adaptation strategies by governments and interested organizations that ultimately benefit small scale farmers livelihoods.

Keywords: climate change adaptation,social ecological systems,poverty,gender,ecosystem services,small scale agriculture,rural livelihoods,community based climate adaptation
Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints. (RapidEx)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Netherlands
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-2-2014, 2014)
Start date: 2015-04-01
End date: 2017-10-31
Duration (months): 31.0
Total project cost (EUR): 1633750.0
EU funding (EUR): 1633750.0
Participants: 1
Project status: CLOSED

There is a pressing need for improvement of the diagnosis of acute myocardial infarction (AMI) for healthcare professionals (HCP). 1–1,5% of the population consult a physician each year with chest pain complaints. While the majority (60–80%) of these patients are sent to a hospital for further inspection, eventually AMI is diagnosed in only 8–18% of these cases. Consequently, a rapid, objective test that helps to better select patients suspected of AMI by HCPs would reduce the number of unnecessary hospital referrals and admissions, thereby saving costs and contributing to a more sustainable healthcare. FABPulous (SME) is a medical device company spun out of Maastricht University in 2008. The core of the company is its innovative proprietary technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages over current technologies in point-of-care and home testing. The CE-marked H-FABP True Rapid Test (H-FABP TRT) developed by FABPulous aids the HCP in ruling out AMI with a very high level of confidence. It is based on the heart-type fatty acid binding protein (H-FABP), which can be used as biomarker for AMI. With H-FABP TRT a physician is able to rule out the occurrence of an AMI for a large proportion of patients suspected of AMI. It is intended for use in both primary and emergency care. In this project FABPulous seeks to medico-economically validate H-FABP TRT in primary (Netherlands+Belgium) and emergency care (UK) by performing two clinical trials. Outcomes of these studies lead to adoption of H-FABP TRT in medical guidelines and form the basis of a request for reimbursement towards health insurers. In this project FABPulous will improve the production process as well in order to decrease the cost price to €5 per test. The addressable market in NW Europe alone amounts to at least 2 mln tests. The phased introduction plan leads to €8.6 mln revenue with a gross margin of €6.5 mln in 2018.

Keywords: h fabp ami
Control-oriented PD state modelling and estimation for precision medicine (con-PDmode)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: Germany
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2020-11-01
End date: 2022-04-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Despite the fact that there has been some progress in developing methods for estimating Parkinson’s disease (PD) symptoms using wearable sensors, these technologies have not sufficiently penetrated the market due to the usability of the system and its cost; existing technologies are constrained by specific hardware requirements or user activities, therefore aversively affecting the cost and usability of the technologies, respectively. Thus, Con-PDmode delivers a software prototype for control-oriented modelling and estimation of PD symptoms that are transparent and platform agnostic. The excellence in innovation potential for successfully bringing the PD assessment tool to the market is the capability to account for inaccuracies and uncertainty in the data collected from low-cost wearable sensors. To this purpose, we will adapt and implement advanced stochastic techniques for improved robustness in state estimation, the confidence level of the model estimation will be transparently communicated to its users. We will perform iterative tests in various environmental and sensor configurations to refine our algorithms as well as the user interface.

Keywords: machine learning,parkinson s disease,wearables,mhealth
deCiphering tHE chemo-mechanical CrosstalK between Macrophages And Tumor cElls (CHECKMATE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-03-15
End date: 2023-03-14
Duration (months): 24.0
Total project cost (EUR): 196707.84
EU funding (EUR): 196707.84
Participants: 1
Project status: CLOSED

Pietro Mascheroni received his training in applied mathematics and mechanics in Italy and has carried out his research in the United States and in Germany. His work lies at the interface between applied mathematics and biology and has been published in prominent journals of the field. He is requesting funding for two years to work with Giovanni Cappello and join his group at LIPhy Grenoble, France. The scientific aim of the project is to improve the understanding of macrophage response to external cues, with the final goal of drawing new insights into the mechanisms of action of immunotherapies. The action will investigate the influence of chemical and mechanical signals on macrophage migration, analyzing their respective importance in determining cell behavior. Taking advantage of the host laboratory’s expertise and facilities, dynamic light scattering will be employed to monitor macrophage migration in 3D scaffolds and tumor aggregates. Macrophages will be stimulated by using different growth factors and chemokines, under variable oxygen and glucose culturing conditions. Mechanical stress will be applied using microfluidic tools and exploiting the osmotic action of Dextran on the extracellular matrix. Relying on the applicant’s expertise, theoretical models based on the active gel theory will be developed to assist the understanding of experimental results. Throughout the project the medical implications of the research will be considered, by taking advantage of collaborations with clinicians of partner institutions. The training program of the action is exhaustive and will allow the researcher to grow as a world-class leader in this field, which is fundamental in healthcare for the benefit of society. He will develop a unique blend of knowledge and expertise, allowing him to communicate and work with applied mathematicians, biomedical scientists and clinicians in industry, health services and academia.

Keywords: dynamic light scattering,cell migration,chemical and mechanical stimuli,mechanical compression
Establishing Eco-design Guidelines for Hydrogen Systems and Technologies (eGHOST)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Research and Innovation actions
Partnership: FCH2 (Art-187)
Countries involved: Spain,Spain,Slovenia,France,France,France,Japan
Call: Development of eco-design guidelines for FCH products (H2020-JTI-FCH-2020-1, 2020)
Start date: 2021-01-01
End date: 2023-12-31
Duration (months): 36.0
Total project cost (EUR): 1133541.25
EU funding (EUR): 998991.25
Participants: 7
Project status: SIGNED

eGHOST will be the first milestone for the development of eco-design criteria in the European hydrogen sector. Two guidelines for specific FCH products (PEMFC stack and SOE) will be completed and the lessons learnt will be integrated in the eGHOST White Book, a reference guidance book for any future eco-design project of FCH systems. eGHOST aims to support the whole FCH sector. Therefore, it addresses the eco-(re)design of mature products (PEMFC stack) and those emerging with TRLs around 5 (SOE) in such a way that sustainable design criteria can be incorporated since the earliest stages of the product development. eGHOST will go a step beyond the current state of the art of eco-design by incorporating eco-efficiency assessment, i.e. combining environmental and economic decision-making tools, and social life cycle assessment to determine the social impacts of the products. Therefore, eGHOST proposes a sustainable (re)design looking at minimizing the economic, environmental and social impacts of the products along their life cycle. Other innovation will be the use of prospective approach for the life cycle thinking tools used to assess the products performance, i.e. to determine the impacts of all the life cycle stages of the product at the time of its occurence. This is required to get valid information of those products at early stages of development. The European Commission considers eco-design as a key factor to fulfil its commitment to a climate-neutral and circular economy in 2050 as identified in different documents (EU Green Deal, New Industrial Strategy for Europe, Circular Economy Directive…). eGHOST will contribute to positioning FCH in this context by developing the first preparatory study of a hydrogen product under the guiding principles of the Eco-design Directive. As well, eGHOST will improve the understanding of FCH technologies as a sustainable investment under the EU Taxonomy, and will enhance Corporate Social Responsibility studies.

Keywords: eco design,guidelines,pemfc stack,white book,life cycle thinking,eco design directive,taxonomy,corporate social responsibility
Role of the stroma-derived ‘alarmin’ IL-33 in anti-viral immunity (STRAVIR)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-10-01
End date: 2018-09-30
Duration (months): 24.0
Total project cost (EUR): 175419.6
EU funding (EUR): 175419.6
Participants: 1
Project status: CLOSED

There is increasing awareness that the recently identified cytokine IL-33 is playing a key role in multiple types of infections and pathologies. It has been recently demonstrated that IL-33 is crucial for mounting an efficient immune response against viral infections as it strongly enhances T cell responses with lack of IL-33 leading to failure in virus control. IL-33 production by stromal cells in lymph nodes (LN) and spleen is crucial for efficient viral clearance, however, the precise cellular source and signals involved in secretion of this nuclear alarmin during viral infection are unknown. In addition, it is poorly understood how this cytokine controls antiviral CD8 T cell function. To determine the cellular source of IL-33 during viral infections, we will assess IL-33 production by the different types of stromal cells present in lymph nodes and spleen during acute viral infection. The Luther lab has the expertise and state-of-the-art facilities to perform in situ characterization and in vivo analysis of stromal cell subsets present in these organs, allowing for the identification of the IL-33 producing population. Using IL-33GFP/+ mice will facilitate the identification of the cellular source of IL-33 during viral infections. Moreover, using in vitro cultures we will study the signals regulating IL-33 release as well as its role in T cells function. All together, the work described aims to increase our understanding of the mechanisms underlying stromal IL-33 secretion and its effects on antiviral T cell responses and wishes to broaden our knowledge on the role of stroma cells regulating immune responses. Importantly, this work could have future implications for antiviral treatments, including the development of better strategies for antiviral treatments including vaccines or immunotherapy.

Keywords: stroma,il 33,anti viral responses,secondary lymphoid organ
Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts (IMMUcan)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Israel,Germany,Germany,Spain,Belgium,Switzerland,Belgium,Belgium,Poland,Belgium,Switzerland,Switzerland,France,France,France,France,United States,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Luxembourg
Call: Human Tumour Microenvironment Immunoprofiling (H2020-JTI-IMI2-2017-13-two-stage, 2017)
Start date: 2019-03-01
End date: 2025-08-31
Duration (months): 78.0
Total project cost (EUR): 35779304.25
EU funding (EUR): 17830000.0
Participants: 32
Project status: SIGNED

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.

Keywords: colorectal,lung,head andand neck,breast,and gastric cancers,immune check point inhibitors,human biological material,immunophenotyping,deecytof,rnaseq,microbiome,bioinformatics,data sharing
Printing cap system with LED UV drying system with improved efficiency and quality (Print4Caps)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Italy
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-05-01
End date: 2018-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

World production for wine and spirits bottle caps is supported by a niche market focused on the manufacturing of offset printing machines for the cylindrical shapes of these items. Due to the intrinsic characteristic of this shape, two independent machines are required, one for the side of the cap, and a different one for the tops. Despite the adoption of UV curable inks around 30 years ago by the offset printing technology in general, this has not been possible for the offset printing machines for the sides of the caps because the plastic deformations produced in the side edging would lead to paint breaking during UV varnish. As a consequence, the total of the caps side globally are printed in ancient solvent-based inks printers, requiring cumbersome conventional ovens for the drying process, with 9 times higher energetic consumption than required by conventional UV technology. In addition, about 20% of caps printed do not reach it final use due to wastage because of read failures, off-centering, tolerances and precision issues. Our project, called Print4Caps, is a new revolutionary off set caps printing machine specific for tops that uses LED UV inks and is built with contained LED UV lamps system to dry the ink. This delivers high quality finishes with centered images with 0.1mm precision. Print4Caps allows the change standard procedures (large ovens or UV ink systems). All in all, we accomplish reducing 90% carbon footprint of the process, avoiding 95% VOC emissions, minimising machine dimensions down to a 10%, increasing productivity by 3 times (30,000 pieces / hour) and decrease the caps waste by 20%. Above all, quality would improve dramatically, reducing off-center error to 0.1 mm (20% of state of the art). All in all, we intend to launch the product in 2021, achieving accumulated profits worth 5.1 M€, a ROI of almost .08 and creating 9 new jobs all within 5 years.

Keywords: offset printing,aluminium,caps,closures,ultraviolet,uv led,machine,manufacturer,mandrel,printing lines,top printing
Superb Atomic LAyer Deposition tool for the semiconductor INdustry (SALADIN)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Sweden,Finland,United Kingdom
Call: Micro- and nanoelectronics technologies (H2020-ICT-2017-1, 2017)
Start date: 2017-11-01
End date: 2021-10-31
Duration (months): 48.0
Total project cost (EUR): 2774375.0
EU funding (EUR): 1935937.5
Participants: 3
Project status: CLOSED

The main objective of SALaDIn project is to prove industrial applicability of Picosun’s Atomic Layer Deposition (ALD) system, called P300F, for the needs of European semiconductor industry. This will be performed in collaboration with Silex Microsystems and Pegasus Chemicals who are responsible for testing and validation of the tool in industrial environment, and supply of chemical precursors for ALD thin films, respectively. The first target market is MEMS (Micro Electro Mechanical Systems) processing and production. The goal is to show that a single ALD system can fulfil the coating needs of MEMS foundry’s multiple devices by meeting film property and quality requirements, flexibility requirements for materials and processes as well as productivity requirements and cost targets for final devices. The system and processes optimized during the project will bring the ALD technology easily accessible and affordable for companies working with wafer sizes other than the mainstream 12” silicon technology and enable cost effective and high quality coatings in various application fields, such as MEMS, LEDs, sensors and devices made on compound semiconductors.

Keywords: atomic layer deposition,thin films,batch tool,ald equipment,automated ald tool,foundry integration,ald processes,mems